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Brugada syndrome (BrS) is associated with the familial sudden death syndrome, and more than 10 genes
have been reported as causative for or modiﬁers of BrS. All gene mutations are related to functional changes
of inward sodium or calcium currents or outward potassium currents. SCN5A was the ﬁrst gene known to
be associated with BrS; it encodes the a-subunit of the cardiac sodium channel. Approximately 20% of BrS
patients in genotyped cases were found to carry SCN5A mutations. The frequency for other BrS-associated
gene mutations is so low that genotype–phenotype correlations for these genes have not been studied to
the same extent as SCN5A-related BrS. In some families with SCN5A mutations, the penetrance of the
mutations is low, and pathophysiological changes in the right ventricular outﬂow tract were reported in
patients with SCN5A mutations. Furthermore, the phenotypes of SCN5A-related BrS can overlap with other
phenotypes, including long QT and sick sinus syndrome, thereby suggesting that SCN5Amutations might be
modiﬁers for BrS, but they do not direct cause BrS. Here, we summarize the genetic background of BrS, with
a particular focus on recent progress in this ﬁeld.
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Brugada syndrome (hereafter referred to as BrS) is character-
ized by a peculiar ST segment (J point) elevation in the right
precordial leads of the electrocardiogram (ECG) as well as idio-
pathic ventricular ﬁbrillation, occurring particularly during sleep,
which often results in nocturnal sudden death. There is a deﬁnite
male predominance in BrS-related morbidity, and men are 10-
times more affected than women. Approximately 20% of the
phenotype-positive probands have a family history of syncope
or sudden death. These clinical features are partially similar to
those previously described as ‘‘Pokkuri’’ disease in Japan [1,2] and
‘‘Lai Tai’’ in Thailand [3]. Indeed, its prevalence is higher in Japan
and Southeastern Asia, which may be partially related to an
Asian-speciﬁc sequence in the promoter region of SCN5A [4].
The disease was named after the report in 1992 by the Brugada
brothers [5], but several case reports on similar ECG ﬁndings and
clinical phenotypes from Italy and Japan were published previously
[1,2,6]. Some of these reports described an associated structural
abnormality, especially in the right-side of the heart, suggesting the
coexistence of subclinical arrhythmogenic right ventricular cardio-
myopathy [7]. Patients with BrS have been shown to carry SCN5A
mutations, which raises the possibility that the speciﬁc structural
change is caused by SCN5A mutations [8,9].
The inheritance pattern of BrS shows an autosomal dominant
mode of transmission. Candidate gene analysis showed that muta-
tions in SCN5Awere responsible for the phenotype of BrS in 3 families,
and over 300 SCN5A mutations have been reported to date [10].
SCN5A encodes for the a subunit of the cardiac sodium
channel, and SCN5A mutations are found in 11–28% of clinically
diagnosed BrS patients [11]. Since 1998, genetic variants in over
10 genes have been reported in patients with BrS. Table 1 lists
these genes, the mutation locations, and the functional changes in
each ion channel current induced by these mutations. In all
genotypes, either the decrease in inward sodium or calcium
currents (INa or ICa) or the increase in outward potassium currents
is thought to be responsible for the BrS phenotype.
BrS is, therefore, a very heterogeneous disease entity from the
perspective of its genetic background. In addition, it is notable
that the genotypes of over two-thirds of BrS patients have not yet
been determined despite extensive genetic testing, which limits
the prognostic value of the genetic tests. Indeed, except for
SCN5A-related BrS, the genotype–phenotype correlation of other
BrS-associated genetic changes is relatively not well studied.
The paucity of genetic studies of BrS is mainly due to the smallTable 1
Brugada syndrome causative genes.
BrS type Gene name Chromosome Function % of probands Reference
BrS1 SCN5A 3p 21–23 INak 11–28% [12]
BrS2 GPD1L 3p 24 INak Rare [44]
BrS3 CACNA1C 12p 13.3 ICak 6.6% [48]
BrS4 CACNB2 10p 12.33 ICak 4.8% [48]
BrS5 SCN1B 19q 13.1 INak 1.1% [53]
BrS6 KCNE3 11q 13–14 Itom Rare [55]
BrS7 SCN3B 11q 23.3 INak Rare [57]
BrS8 KCNJ8 12p11.23 IKATPm 2% [61]
BrS9 CACNA2D1 7q21-22 ICak 1.8% [49]
BrS10 KCND3 1p13.3 Itom Rare [63]
BrS11 MOG1 17p13.1 INak Rare [65]
BrS12 SLMAP 3p21.2-p14.3 INak Unknown [66]
BrS13 SCN2B 11q23 INak Unknown [67]
Other genes
KCNH2 7q36.1 IKrm Unknown [64]
HCN4 15q24.1 Ifk Unknown [71]
KCNE5 Xq 22.3 Itom Unknown [70]number of families with a history of BrS that have been geno-
typed. Presently, genetic testing is only diagnostic; however, once
the proband is successfully genotyped, for example as a carrier of
SCN5A mutation, the mutation-speciﬁc genetic test would be
highly recommended for family members because it can deter-
mine the relatives that are at a potential risk for BrS and BrS-
related death. In this review, we summarize the genetic basis of
BrS, with a particular focus on recent reports.2. SCN5A (BrS type 1 [BrS1])
Voltage-gated sodium channels are essential for modulating the
amplitude and upstroke velocity of the cardiac action potential,
which are parameters that are important determinants of impulse
propagation and conduction velocity through the myocardium.
Functional analyses using patch-clamp techniques in a heterolo-
gous expression system demonstrated that most of the SCN5A
mutations had a loss-of-function effect, primarily manifested as a
failure of intracellular trafﬁcking to the cell membrane or mal-
function of gating kinetics [12–15]. Surprisingly, SCN5A mutations
are associated with different phenotypes, in addition to BrS, even
among members of the affected family (Fig. 1). These phenotypes
include long QT syndrome (type 3) [16–21], progressive cardiac
conduction defects [22–25], sick sinus syndrome [26–29], familial
atrial ﬁbrillation [30–32], early repolarization syndrome [33],
dilated cardiomyopathy [34–36], and sudden infant death syn-
drome [37–39]. Very recently, a French research group reported an
SCN5A R222Q mutation in 3 unrelated families with multifocal
ectopic Purkinje-related premature contractions (MEPPC) and
demonstrated that the mutation caused a gain-of-function of the
cardiac sodium channel [40]. Even in a single patient, these
phenotypes can overlap (so-called overlap syndrome). Character-
istic clinical features differentiate the SCN5A-related BrS from other
forms of BrS and can help predict the genetic diagnosis of BrS. The
appearance of overlap phenotypes seems to be mutation-speciﬁc.
For example, the SCN5A E1784K mutant has been linked to not
only BrS but also long QT and familial sick sinus syndrome [19].
Though they are the most studied among BrS-associated genes,
SCN5A genotype–BrS phenotype correlations remain controver-
sial. According to numerous functional assays, there is convincing
data for the hypothesis that the biophysical effects of SCN5A
mutations identiﬁed in BrS patients account for their phenotype.
However, in extensive surveys of family members, SCN5A muta-
tions were also identiﬁed in phenotype-negative individuals [41].
On the contrary, in a study on 13 BrS families containing Z5
BrS patients [42], 8 individuals presented with typical type 1 BrSSCN5
BrS
SSSDCM
LQTSERS
FAF PCCD
SIDS MEPPC
Fig. 1. Scheme showing the multiple cardiac phenotypes that are associated with
SCN5A mutations. DCM, dilated cardiomyopathy; ERS, early repolarization syn-
drome; FAF, familial atrial ﬁbrillation; LQTS, long QT syndrome (type 3); MEPPC,
multifocal ectopic Purkinje-related premature contractions; PCCD, progressive
cardiac conduction defects; SIDS, sudden infant death syndrome; SSS, sick sinus
syndrome.
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that mutations in SCN5A alone do not directly cause but work as
modiﬁers to increase the likelihood of developing the BrS pheno-
type in some BrS patients.3. GPD1L (BrS2)
In 2002, the second candidate locus of BrS was discovered on
chromosome 3p22-25 in a large Italian family by using linkage
analysis [43]. The sodium channel genes located on that locus,
SCN5A, SCN10A, and SCN12A, on chromosome 3 were excluded as
candidates in the family. Therefore, London et al. [44] further
searched and narrowed the BrS-associated region to 1 million bp
on chromosome 3p24. Although 4 known genes were located on
this region, they were eliminated by single-strand conformational
polymorphism (SSCP) and/or direct sequencing. In the linkage
region, RNA from 2 genes of unknown function in the heart was
identiﬁed using reverse-transcriptional polymerase chain reaction
(PCR) and direct sequencing. Finally, a missense mutation was
detected in one of the genes. The gene was GPD1L (NM_015141),
and the mutation was a C/T base-pair change (C899T) leading to an
alanine-to-valine substitution at amino acid 280 (A280V). The co-
expression of SCN5A and GPD1L-A280V, but not SCN5A and wild-
type (WT) GPD1L, in human embryonic kidney (HEK) cells sig-
niﬁcantly changed the amplitude of INa. The data also showed that
the trafﬁcking deﬁciency of Nav1.5 to the cell surface was the
underlying mechanism responsible for decreased INa. Following
this report, 3 novel GPD1L mutations, corresponding to E83K,
I124V, and R273C in GPD1L protein, were identiﬁed in 304 cases
of sudden infant death syndrome [45]. In the functional analyses, all
mutant channels showed a reduction in the INa current. A study on
80 Japanese BrS patients in Asia by Makiyama and his colleagues did
not identify any GPD1L mutations [46]. The relevance of GPD1L
mutations in Asian BrS patients needs further study.4. CACNA1C (BrS3), CACNB2 (BrS4), and CACNA2D (BrS9)
The L-type calcium channel (LTCC) in heart consists of 4 sub-
units: a1, b2, a2, and d [47], encoded by CACNA1C, CACNB2, and
CACNA2D, respectively, with the a2 and d subunits encoded by
the gene CANA2D. In 2007, Antzelevitch et al. [48] reported 2
CACNA1C mutations and a CACNB2 mutation from a genotype
survey of 82 BrS patients. The corresponding protein mutations
were A39V and G490R in CACNA1C and S481L in CACNB2.
Carriers of all 3 mutations exhibited short QT intervals, lower
than 360 ms, with a coved-type ST elevation in ECG evaluations.
Therefore, BrS patients with LTCC mutations were considered to
have short QTc intervals. In their subsequent study, they identi-
ﬁed 15 and 5 mutation carriers in a cohort of 152 and 10
probands diagnosed with BrS and BrS with short QT intervals,
respectively [49]. Eight mutations were detected in CACNA1C, 6 in
CACNB2, and 3 in CACNA2D. We also screened 191 BrS and IVF
patients who were negative for SCN5A mutations and identiﬁed 2
CACNA1C mutations in 2 BrS patients [50].
Functional analysis using patch-clamp methods was per-
formed to address the impact of the 4 CACNA1C mutations
(A39V, G490R, V2014I, and E1829-Q1833dup) and 1 CACNB2
mutation (S481L) reported thus far [48,49]. Current densities in
cells expressing any of the mutant LTCCs were decreased, and the
expression of one of the mutants, A39V, impaired cell surface
trafﬁcking of Ca(v)1.2. The number of LTCC mutations identiﬁed
in BrS patients and that of mutants whose channel functions have
been analyzed, are small compared to SCN5A mutations. Furtherinvestigation is essential to elucidate the pathophysiology of BrS
patients with LTCC mutations.5. SCN1B (BrS5)
The sodium channel is composed of a pore-forming a subunit
and auxiliary function-modifying b subunits [51]. In humans, 4 b
subunits have been identiﬁed [52]. Among these, SCN1B encodes one
of the b subunits, b1. In 2008, Watanabe et al. [53] reported a novel
mutation, W179X, in SCN1B from a survey of 282 BrS patients.
The mutation was located in the transcriptional variant b1B, which
had an alternative 30 sequence. ECG analysis of the proband with the
SCN1Bmutation showed an ST segment elevation, which is typical of
BrS, and conduction abnormalities (prolonged PR interval of 220 ms
and left anterior hemiblock). In functional analysis, co-expression of
Nav1.5 and WT b1B increased the INa densities and evoked a
negative shift in the activation and inactivation curves, whereas
these effects were diminished in cells co-expressing Nav1.5 and the
W179X b1B mutant.6. KCNE3 (BrS6)
KCNE3 is a homolog of KCNE1, which encodes MinK, and the
protein encoded by KCNE3 is called MinK-related protein 2
(Mirp2). Thus far, 5 KCNE genes have been identiﬁed and all
genes encode auxiliary b subunits, which modify many kinds of
potassium channels [54]. In a screening study of 105 BrS patients,
an R99H Mirp2 mutation was found in a proband who was
resuscitated from cardiac arrest [55]. In the analysis of the index
family, all 4 mutation carriers showed ST segment elevation,
whereas 3 non-carriers had normal ECG. In the normal condition,
Mirp2 decreased the transient outward potassium current (Ito).
However, the suppression of Ito by the R99H Mirp2 mutant was
smaller than that mediated by the WT protein, and the effect was
observed even upon co-expression of the WT and R99H. These
results showed that expression of the R99H mutant increased the
Ito densities and caused BrS. Recently, another KCNE3 mutation,
corresponding to T4A in Mrip2, was identiﬁed in a Japanese BrS
patient [56]. This mutation also failed to suppress the Ito.7. SCN3B (BrS7)
SCN3B encodes the b3 subunit of the sodium channel. An
SCN3B-mutation, corresponding to L10P in b3, was identiﬁed in a
64-year-old man [57]. The patient was asymptomatic and his ECG
showed coved-type ST elevation upon provocation by procaina-
mide. In a heterologous expression system, WT b3 increased the
INa densities, whereas co-expression of the WT b3 and L10P b3
strongly decreased the INa densities. The gating of the cardiac
sodium channel also changed in cells with L10P b3 and the
inactivation curve of the mutant channel moved negatively,
which caused the reduction in the total INa. Furthermore, expres-
sion of L10P b3 disturbed the normal trafﬁcking of the cardiac
sodium channel to the membrane. More recently, another SCN3B
mutation, corresponding to V110I in b3, was identiﬁed in 3 of 178
Japanese BrS patients [58]. Transfection of HEK 293-derived cells
with V110I b3 impaired the cytoplasmic trafﬁcking of Nav1.5 and
decreased the cell surface expression of Nav1.5.
8. KCNJ8 (BrS8)
A KCNJ8 mutation, corresponding to an S422L mutation in
the protein, was ﬁrst identiﬁed in a 14-year-old girl with early
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encodes Kir6.1, which has 2 transmembrane regions, and the KATP
channel is composed of a complex of Kir6.1 or Kir6.2 and the
sulfonylurea receptor (SUR) [60]. In a subsequent report, 87 BrS
patients were genetically screened for changes in KCNJ8 and one
asymptomatic BrS patient was identiﬁed with the S422L mutation
[61]. A coved-type ST elevation in ECG evaluations of this patient
was unmasked after ﬂecainide administration. To conﬁrm the
functional effect of the S422L mutation, glibenclamide-sensitive
KATP currents were recorded in cells co-expressing Kir6.1 and
SUR2. The results showed that KATP current density of Kir6.
1-S422L mutant channels was remarkably increased compared
to that of the Kir6.1-WT channels.9. KCND3 (BrS10)
KCND3 encodes Kv4.3, which is the a subunit of the potassium
channel that modulates Ito. The differences of Ito densities
between the endocardium and epicardium, or the increase of Ito
in the epicardium have been discussed as mechanisms underlying
BrS [62]. Therefore, KCND3 was expected to be a strong candidate
gene, and indeed, 2 KCND3mutation carriers were identiﬁed from
86 BrS patients in whom no mutations were detected in other
reported BrS genes [63]. The ﬁrst patient with the Kv4.3-L450F
mutation was a 45-year-old man with a history of heart palpita-
tions at rest. His ECG showed slight ST elevation; therefore, he
underwent a ﬂecainide challenge test that induced a type 1 ECG
pattern. Another patient with the Kv4.3-G600R mutation was a
22-year-old man with a history of heart palpitations and pre-
syncope. He was discovered unconscious and unresponsive in
bed. The 12-lead ECG examination conducted after hospitalization
revealed ST segment elevation in V1, V2, and V3. In the functional
analysis of the mutants in cells, co-expression of both Kv4.3
mutants with KChip2 increased the Ito densities, and the deacti-
vation time constant of the Kv4.3-G600R channel was slower than
that of the WT. Computer simulations revealed that both Kv4.3
mutations caused a loss of the action potential dome of recon-
stituted right ventricular (RV) epicardial action potentials.10. MOG1 (BrS11)
MOG1 is a recently identiﬁed protein that modiﬁes the
expression and trafﬁcking of Nav1.5 [64]. A MOG1-E83D mutation
was identiﬁed in a 40-year-old woman who was resuscitated
from cardiac arrest [65]. Her ECG showed ST elevation and an
atypical right branch block just after the resuscitation. The ST
elevation was normalized 24 h later. The functional analysis of
MOG1-E83D by using patch-clamp methods showed decreased
INa, and expression of the mutant in cells decreased the levels of
Nav1.5 on the cell membrane.11. SLMAP (BrS12)
Recently, 2 mutations in SLMAP were reported to cause BrS
[66]. SLMAP encodes sarcolemmal membrane-associated protein
(SLMAP) that localizes at T-tubules. The functions of SLMAP have
not been well elucidated. The mutations, V269I and E710A, were
identiﬁed in a 46-year-old and a 57-year-old male patient,
respectively, and both of them experienced syncope and showed
spontaneous saddle-back (V269I) or coved-type (E710A) ST ele-
vation. To elucidate the functional effect of SLMAP mutations on
the cardiac INa, SLMAP-WT or mutants were co-expressed with
NaV1.5. The results showed that INa in cells co-expressing SLMAP-
V269I or E710A with NaV1.5 were signiﬁcantly lower than thatco-expressing the WT protein. Moreover, membrane surface
expression of Nav1.5 was impaired in cells harboring the
mutant SLMAP.12. SCN2B (BrS13)
More recently, another b subunit of the sodium channel,
SCN2B, was reported to be a candidate gene involved in BrS
[67]. Three mutations, corresponding to R28Q, –Y69H and –P210L
in the b2 subunit, were identiﬁed in 4 patients from a survey of
269 BrS patients. In the functional analysis, INa in cells with the
mutant b2 were decreased compared to those with the WT
protein, and all the mutants perturbed normal trafﬁcking of
Nav1.5 to the membrane.13. Other candidate genes
13.1. KCNH2
KCNH2 is well known as the causative gene of long QT
syndrome type 2, and it encodes Kv11.1, which is a constituent
of the IKr channel. In 2005, 2 KCNH2 mutations, corresponding to
G873S and N985S in Kv11.1, were detected in two asymptomatic
BrS patients [68]. Both mutant channels increased the IKr current.
Subsequently, another KCNH2 mutation was identiﬁed in an
asymptomatic BrS patient with short QT interval and that mutant
channel also increased the IKr current [69]. The patients with
KCNH2 mutations showed atypical BrS phenotypes; therefore,
KCNH2 was considered a modiﬁer that conﬁgures the ECG pattern
in various BrS types.13.2. KCNE5 (KCNE1L)
KCNE5 is a member of the KCNE gene family and encodes an
auxiliary subunit of the potassium channel. Gender differences in
BrS prevalence are well known, although the underlying reason is
not fully elucidated. The KCNE5 gene is located on the X chromo-
some. In 2009, 2 KCNE5 mutations, corresponding to Y81H and
D92E-E93X on the protein, were identiﬁed in these BrS patients
[70]. Although KCNE5 modiﬁes many kinds of potassium chan-
nels, changes to the Ito were suspected to be affected by KCNE5
mutants to reproduce the phenotype of BrS. When co-expressed
with Kv4.3, which encodes the a subunit of Ito, the mutant KCNE5
channels increased the Ito densities. On the other hand, Ito
densities in cells co-expressing KCNE5-WT and mutants were
almost the same as those expressing KCNE5-WT alone. This
difference may explain the gender difference in BrS, such that
an intact WT copy of KCNE5 on the second X chromosome may
provide protection from BrS in female patients.13.3. HCN4
HCN4 encodes the If channel, also known as the pacemaker
channel. In 2009, a splice mutation in HCN4 was identiﬁed in BrS
patients [71], and a simulation model that integrated a ventri-
cular action potential of the If channel (Tusscher–Noble–Noble–
Panﬁlov model) [72] showed that the If channel likely contributed
to the shortening of the action potential duration and the
prevention of early after-depolarization in bradycardia. These
observations suggested that the If channel plays a preventive role
in triggering bradycardia-induced ventricular arrhythmias.
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As mentioned above, more than 10 genes have been reported to
cause BrS. The proportions of BrS patients who are mutation carriers,
however, are very small, except in the case of SCN5A. In a recent
extensive mutation analysis of 129 BrS1 through BrS12 patients
[73], 27 patients had a putative pathogenic mutation (21 patients
with an SCN5A mutation, 2 with a CACNB2B mutation, and 1 each
with a mutation in KCNJ8, KCND3, SCN1Bb, and HCN4) [73].15. Other types of mutations in BrS patients
Generally, mutation analysis is performed by PCR-based direct
sequencing. However, the method has been known to fail in
detecting large-scale rearrangements of genes. In a 14-year-old
BrS patient, a deletion of exon 9 and 10 in the SCN5A gene was
identiﬁed using multiplex ligation-dependent probe ampliﬁcation
(MLPA) methods [74]. In another cohort of 76 BrS patients
screened for SCN5A mutations [75], no patient carried a large
insertion/deletion abnormality. The frequency of large-scale gene
rearrangements of SCN5A seems to be low; however, we have to
keep in mind the limitations of direct sequencing methods,
including next-generation sequencing methods, for detecting
mutations.16. Conclusion
In the past 2 decades, an increasing number of mutations in
over 10 genes have been reported in patients with BrS. With the
exception of SCN5A-related BrS, the genotype–phenotype rela-
tions have not been completely characterized, likely due to the
availability of a relatively small number of genotyped families.
With regard to SCN5A-related BrS, although originally thought of
as a separate disease entity, various arrhythmias are concurrently
associated with SCN5A mutations (overlap syndromes). In the
clinical setting, this particular ﬁnding may help in the diagnosis of
SCN5A-related arrhythmia syndrome.Conﬂict of interest
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